ANDREWS, Steven W.;ARONOW, Sean;BLAKE, James F.;BRANDHUBER, Barbara J.;COOK, Adam;HAAS, Julia;JIANG, Yutong;KOLAKOWSKI, Gabrielle R.;MCFADDIN, Elizabeth A.;MCKENNEY, Megan L.;MCNULTY, Oren T.;METCALF, Andrew T.;MORENO, David A.;TANG, Tony P.;REN, Li
发明人:
ANDREWS, Steven W.,ARONOW, Sean,BLAKE, James F.,BRANDHUBER, Barbara J.,COOK, Adam,HAAS, Julia,JIANG, Yutong,KOLAKOWSKI, Gabrielle R.,MCFADDIN, Elizabeth A.,MCKENNEY, Megan L.,MCNULTY, Oren T.,METCALF, Andrew T.,MORENO, David A.,TANG, Tony P.,REN, Li
申请号：
WO2017US55983
公开号：
WO2018071447(A1)
申请日:
2017.10.10
申请国别(地区):
世界知识产权组织国际局
年份:
2018
代理人:
摘要：
Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
